HUTCHMED (China) Limited (HKG:0013)
24.10
+0.15 (0.63%)
Jun 6, 2025, 4:08 PM HKT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
2.70M HKD
Profits / Employee
161.82K HKD
Market Cap
20.42B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
BeOne Medicines | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
Innovent Biologics | 5,659 |
CSPC Pharmaceutical Group | 21,400 |
WuXi Biologics | 12,575 |
Sino Biopharmaceutical | 24,379 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
HUTCHMED (China) News
- 3 days ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 6 days ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 16 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 17 days ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 6 weeks ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 6 weeks ago - AIM Market Roundup: Catenai, Seeen, Hutchmed - The Armchair Trader
- 6 weeks ago - HUTCHMED Completes Enrollment for Phase II Trial of Savolitinib in Gastric Cancer | HCM stock news - GuruFocus
- 6 weeks ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire